摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氯-2-氟异烟酸 | 741683-19-2

中文名称
3-氯-2-氟异烟酸
中文别名
——
英文名称
2-fluoro-3-chloro-4-pyridinecarboxylic acid
英文别名
3-Chloro-2-fluoroisonicotinic acid;3-Chloro-2-fluoropyridine-4-carboxylic acid
3-氯-2-氟异烟酸化学式
CAS
741683-19-2
化学式
C6H3ClFNO2
mdl
MFCD09031169
分子量
175.547
InChiKey
PYLURACOOBPBPM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    154 °C (decomp)(Solv: ethyl acetate (141-78-6); hexane (110-54-3))
  • 沸点:
    404.1±40.0 °C(Predicted)
  • 密度:
    1.576±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    50.2
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:6d32bb2c1144a852c1986423d69580df
查看

反应信息

  • 作为反应物:
    描述:
    3-氯-2-氟异烟酸copper(l) iodide 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 caesium carbonate1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 4.0h, 生成
    参考文献:
    名称:
    [EN] AROMATIC AMINE DERIVATIVES AND PREPARATION METHOD AND MEDICAL USE THEREOF
    [FR] DÉRIVÉS D'AMINES AROMATIQUES ET LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION MÉDICALE
    [ZH] 芳胺类衍生物及其制备方法和医药用途
    摘要:
    本公开涉及芳胺类衍生物及其制备方法和医药用途。具体地,涉及通式(I)所示的化合物,其制备方法,含有其的药物组合物,以及其作为Toll样受体(TLR)激动剂用于治疗与TLR8活性相关的疾病的用途。通式(I)中的各基团的定义与说明书中的定义相同。
    公开号:
    WO2023078241A1
  • 作为产物:
    描述:
    2,3-二氯吡啶正丁基锂二异丙胺 、 cesium fluoride 作用下, 以 四氢呋喃N-甲基吡咯烷酮正己烷 为溶剂, 反应 24.5h, 生成 3-氯-2-氟异烟酸
    参考文献:
    名称:
    EP1726590
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • [EN] HYDROXY-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE SUBSTITUÉS PAR UN GROUPE HYDROXY
    申请人:MERCK SHARP & DOHME
    公开号:WO2014176142A1
    公开(公告)日:2014-10-30
    The present invention is directed to hydroxy compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    本发明涉及对促进素受体的拮抗剂的羟基化合物。本发明还涉及所述化合物在潜在治疗或预防涉及促进素受体的神经和精神障碍和疾病中的用途。本发明还涉及包含这些化合物的药物组合物。本发明还涉及这些药物组合物在预防或治疗涉及促进素受体的疾病中的用途。
  • Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
    申请人:Moriya Minoru
    公开号:US20060106046A1
    公开(公告)日:2006-05-18
    The invention provides melanin-concentrating hormone receptor antagonists containing as the active ingredient piperidine derivatives represented by the general formula [I]: [wherein R 1 is hydrogen, hydroxyl, lower alkyl, or the like; R 2 , R 3a , R 3b , R 4a , R 4b , R 5a , R 5b and R 6 each stands for hydrogen, halogen, or the like; W 1 and W 2 each independently stands for —O—, —CH 2 —, or the like; Y 1 , Y 2 , Y 3 and Y 4 stand for —CH—, —CF—, —N—, or the like; Z stands for lower alkyl, an aliphatic heterocyclic group, or the like; Ar is a mono- or bi-cyclic aliphatic heterocycle or an aromatic heterocycle; and n is an integer of 1 to 8]. The compounds act as antagonist against melanin-concentrating hormone receptor and are useful as drugs for central diseases, circulatory diseases, or metabolic diseases.
    本发明提供一种含有作为活性成分的吡啶衍生物黑色素浓集激素受体拮抗剂,其通式表示为[I]:[其中R1为、羟基、低级烷基或类似物;R2、R3a、R3b、R4a、R4b、R5a、R5b和R6各自代表、卤素或类似物;W1和W2各自独立地代表—O—、—CH2—或类似物;Y1、Y2、Y3和Y4代表—CH—、—CF—、—N—或类似物;Z代表低级烷基、脂环族杂环基或类似物;Ar为单环或双环脂环族杂环或芳香族杂环;n为1至8的整数]。这些化合物作为黑色素浓集激素受体的拮抗剂,并且可用于中枢疾病、循环系统疾病或代谢性疾病的药物。
  • Aza-Substituted Spiro Derivatives
    申请人:Jitsuoka Makoto
    公开号:US20090258871A1
    公开(公告)日:2009-10-15
    A compound of the following formula (I) or its pharmaceutically-acceptable salt is provided: [wherein X, Y, Z and W each independently represent a methine group or a nitrogen atom, provided that a case where all of X, Y, Z and W are methine group; A represents —O— or the like, B represents —C(O)— or the like, D represent —(CH 2 )m 2 -, —O— or the like, and m2 represents 0 or 1; Q represents a methine group or a nitrogen atom; and R represents a group represented by the following formula (II-1) (wherein R 6 , R 7 and R 8 independently represent a lower alkyl group or the like].
    提供以下式子(I)的化合物或其药学上可接受的盐:[其中X、Y、Z和W各自独立地表示甲基基团或原子,前提是当X、Y、Z和W全部为甲基基团时;A表示—O—或类似物,B表示—C(O)—或类似物,D表示—(CH2)m2-、—O—或类似物,m2表示0或1;Q表示甲基基团或原子;R表示由以下式子(II-1)表示的基团(其中R6、R7和R8各自独立地表示较低的烷基基团或类似物)。
  • 3-Arylamino pyridine derivatives
    申请人:Abel Ulricn
    公开号:US20090093462A1
    公开(公告)日:2009-04-09
    The invention provides novel, substituted 3-arylamino pyridine compounds (I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.
    本发明提供了新型的取代的3-芳基氨基吡啶化合物(I),其药学上可接受的盐、溶剂和前药化合物,其中W、R1、R2、R9、R10、R11、R12、R13、R14如规范中所定义。这些化合物是MEK抑制剂,可用于治疗高增殖性疾病,如癌症、再狭窄和炎症。本发明还揭示了在哺乳动物,特别是人类中治疗高增殖性疾病的这些化合物的用途,以及包含这些化合物的制药组合物。
  • Cycloalkanopyridine derivative
    申请人:Takahashi Hirobumi
    公开号:US20070191419A1
    公开(公告)日:2007-08-16
    Provided are cycloalkanopyridine derivatives of formula [I]: [wherein the symbols are the same as those stated in the description]. The compounds act as a nociceptin receptor antagonist, and are useful as medicines for diseases associated with a nociceptin receptor, for example, as a reliever against tolerance to a narcotic analgesic; a reliever against dependence on or addiction to a narcotic analgesic; an analgesic enhancer; an antiobesitic or appetite suppressor; a treating or prophylactic agent for cognitive impairment and dementia/amnesia; an agent for treating developmental cognitive abnormality; a remedy for schizophrenia; an agent for treating neurodegenerative diseases; an anti-depressant or treating agent for affective disorder; a treating or prophylactic agent for diabetes insipidus; a treating or prophylactic agent for polyuria; or a remedy for hypotension.
    提供的是式[I]的环烷吡啶衍生物:[其中符号与说明中所述相同]。这些化合物作为一种nociceptin受体拮抗剂,可用作与nociceptin受体相关的疾病的药物,例如作为缓解对麻醉镇痛剂的耐受性的药物;对麻醉镇痛剂的依赖或成瘾的缓解剂;镇痛增强剂;抗肥胖或食欲抑制剂;治疗或预防认知障碍和失忆症的药物;治疗发育性认知异常的药物;治疗精神分裂症的药物;治疗神经退行性疾病的药物;抗抑郁或治疗情感障碍的药物;治疗或预防尿崩症的药物;治疗或预防多尿症的药物;或治疗低血压的药物。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S,2'S)-(-)-[N,N'-双(2-吡啶基甲基]-2,2'-联吡咯烷双(乙腈)铁(II)六氟锑酸盐 (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 (1'R,2'S)-尼古丁1,1'-Di-N-氧化物 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸氯苯那敏-D6 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 韦德伊斯试剂 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非布索坦杂质66 非尼拉朵 非尼拉敏 雷索替丁 阿雷地平 阿瑞洛莫 阿扎那韦中间体 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 镉,二碘四(4-甲基吡啶)- 锌,二溴二[4-吡啶羧硫代酸(2-吡啶基亚甲基)酰肼]-